1. Home
  2. PNI vs ANTX Comparison

PNI vs ANTX Comparison

Compare PNI & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pimco New York Municipal Income Fund II of Beneficial Interest

PNI

Pimco New York Municipal Income Fund II of Beneficial Interest

SELL

Current Price

$6.34

Market Cap

153.3M

Sector

Finance

ML Signal

SELL

Logo AN2 Therapeutics Inc.

ANTX

AN2 Therapeutics Inc.

SELL

Current Price

$4.22

Market Cap

172.9M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
PNI
ANTX
Founded
2002
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
153.3M
172.9M
IPO Year
2002
2022

Fundamental Metrics

Financial Performance
Metric
PNI
ANTX
Price
$6.34
$4.22
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
★ $9.00
AVG Volume (30 Days)
76.3K
★ 236.2K
Earning Date
01-01-0001
11-09-2026
Dividend Yield
★ 4.76%
N/A
EPS Growth
N/A
★ 32.56
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.96
$1.00
52 Week High
$7.20
$7.19

Technical Indicators

Market Signals
Indicator
PNI
ANTX
Relative Strength Index (RSI) 45.11 49.94
Support Level $5.96 $3.89
Resistance Level $7.10 $5.11
Average True Range (ATR) 0.09 0.39
MACD -0.02 0.07
Stochastic Oscillator 13.16 45.83

Price Performance

Historical Comparison
PNI
ANTX

About PNI Pimco New York Municipal Income Fund II of Beneficial Interest

PIMCO New York Municipal Income Fund II is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State, and New York City income tax. The fund's portfolio comprises investments across sectors such as education, transportation, healthcare, and others.

About ANTX AN2 Therapeutics Inc.

AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.

Share on Social Networks: